O15Characteristics of people obtaining abortions in states likely to ban it: Findings from a 2021–2022 national study

      This paper is only available as a PDF. To read, Please Download here.


      To understand who is being impacted by the recent Dobbs v. Jackson Women's Health Organization decision.


      We recruited a random sample of US facilities that provide abortion care and asked them to enroll patients to fill out a 10-minute online survey. Fielding began in June 2021 and ended in June 2022. We compare respondents living in “safe” states with those in the 21 states most likely to ban abortion when Roe is overturned (“post-Roe”).


      Our analytic sample used information from 5,241 individuals obtaining abortions at 58 clinics and residing in 41 states. Some 62% of the sample resided in safe states and 38% in post-Roe states. Compared with respondents in safe states, those in post-Roe states were more likely to be non-Hispanic Black (40% vs. 25%), non-Hispanic White (36% vs. 29%) and to obtain medication abortions (60% vs. 49%). Some 15% in post-Roe states traveled out of state for care, but the majority (57%) were traveling from one post-Roe state to another. In safe states, 50% of respondents reported paying $0 for the abortion compared with 5% of those in post-Roe states. Most respondents in post-Roe states were paying out of pocket (87%) and nearly one in five (20%) also relied on financial assistance. In turn, a majority reported that it was difficult to pay for the abortion (56%), and one-third had a hard time coming up with the money.


      The financial difficulties faced by people obtaining abortions in post-Roe states will be further exacerbated if they have to travel further out of state for care.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect